This is peer information, not medical advice. Spacing doses further apart than labeled is off-label. Talk to your prescriber before changing your schedule.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are approved as once-weekly injections. In practice, some people stretch that to every 10 days, every two weeks, or longer. Usually the reason is cost or supply, sometimes side effects, and often a hope of using less medication once the weight has come off. The question underneath is a fair one: if the goal is maintenance rather than more loss, do you need the full weekly dose?
The short answer right now is "possibly, for some people, but nobody has tested it properly." This guide walks through what spacing does to the amount of drug in your body, what the early evidence found, and what to plan for if you and your prescriber decide to try it.
Why the label says weekly
These drugs are dosed weekly because they leave the body slowly. The prescribing information puts semaglutide's half-life at about one week (Wegovy label (external link)) and tirzepatide's at about five days (Zepbound label (external link)). A half-life is how long it takes for half of a dose to clear.
That slow clearance is why a missed dose isn't an emergency, and it's also why spacing doses out doesn't drop you off a cliff. But it does change your levels in two ways.
Your average exposure drops in proportion to the gap. Averaged over time, the amount of drug in your system depends on how much you take and how often. Taking the same dose every 10 days gives you roughly 70% of the weekly average. Every 14 days gives you about half. That arithmetic holds whatever the half-life is.
Your low points get lower. Because tirzepatide clears faster, spacing affects it more at the tail end of each gap:
| Days after a dose | Semaglutide left (half-life ~7 days) | Tirzepatide left (half-life ~5 days) |
|---|---|---|
| 7 | ~50% | ~38% |
| 10 | ~37% | ~25% |
| 14 | ~25% | ~14% |
These are simple single-dose estimates, not measurements, and your real levels depend on your weight, how long you've been on the drug, and your dose. The point is the direction: on a two-week schedule, the second week runs on much less medication than the first. Many people describe that as appetite and "food noise" creeping back before the next shot, which is exactly what the numbers predict.
What the evidence actually shows
There are no randomized trials of stretched dosing. What exists is small and early.
A 30-person case series (2026). Doctors at Scripps Clinic reviewed patients whose weight had plateaued on weekly semaglutide or tirzepatide (less than 5% change over three months) and who were then offered every-other-week dosing at their current dose. Of 38 who were interested, 4 never actually switched and 4 went back to weekly dosing because weight was creeping up. The 30 who stayed on the reduced schedule were followed for an average of 36 weeks. Most injected every two weeks or longer, up to six weeks, and six injected every 10 to 14 days. Their average weight went from 74.1 kg at plateau to 72.4 kg, so they held their loss and shed a little more. Blood sugar, triglycerides, and blood pressure gains held too (Wong et al., Obesity, 2026, DOI (external link)).
That's encouraging, but it's a very specific group. People only switched after a plateau, most had reached a BMI around 25, only two had class 2 or 3 obesity, 26 of 30 were White, and nobody was randomized or compared with a control group. People motivated enough to try de-escalating may also be doing more of everything else. The authors say plainly that larger randomized trials are needed. Body composition was measured with bioimpedance, which has real limits. One author is a trial investigator for both drug makers.
Two patients and a computer model (2025). A separate report described two people who kept most of their weight loss while dosing less often, paired with a pharmacokinetic model of "virtual patients" suggesting that most weight loss could persist with gaps of two, three, or perhaps four weeks. The authors call it a hypothesis to test, not a protocol (Wu et al., Obesity, 2025, DOI (external link)).
Where it fits in the bigger picture. A 2026 review argued that long-term care shouldn't be a binary choice between full dose forever and stopping. It lists reduced-frequency dosing as one option alongside a lower dose, switching to an oral form, and structured lifestyle support, while stressing that none of these has been prospectively validated (van Bruggen et al., Obesity Pillars, 2026, DOI (external link)). The closest thing to a proper trial is SURMOUNT-MAINTAIN, which tested a lower weekly dose rather than a longer gap. That approach has randomized evidence behind it, covered in our guide on tapering vs. staying on a maintenance dose.
The risk you're managing: less drug can drift toward no drug
The reason to be careful is what happens when these medications stop entirely. In the STEP 4 trial, people who switched from semaglutide to placebo gained back 6.9% of their body weight over the next 48 weeks, while those who continued lost another 7.9% (Rubino et al., JAMA, 2021, DOI (external link)). A 2026 analysis of 37 studies estimated that after stopping semaglutide or tirzepatide, weight comes back at about 0.8 kg a month, with a projected return to starting weight in about a year and a half (West et al., BMJ, 2026, DOI (external link)).
Stretching isn't stopping. But every extra day between doses moves your exposure a little closer to zero, and nobody yet knows where the line is for any individual. That's why the early studies watched weight closely and let people return to weekly dosing when it climbed.
Practical risks to plan around
- GI side effects when you "catch up." Tolerance to nausea and other GI effects is built during titration and fades with low drug levels. Long gaps followed by a full dose can bring side effects back. In one 2026 case report, a woman who had tolerated semaglutide for about a year took a five-week break, restarted at her full 2.4 mg dose, and was hospitalized for four days with severe vomiting, diarrhea, and electrolyte problems. The authors recommend restarting at a lower dose after long interruptions (Valizada & Zilbermint, Cureus, 2026, DOI (external link)). Very long gaps get close to the point where some labels, including Wegovy's, advise restarting the titration ladder; see restarting after a gap.
- Don't double up. Taking a larger dose to make up for a longer gap is a different and riskier move. See what to do if you miss a dose and accidental double doses.
- Compounded vials add error risk. Stretching often goes together with drawing custom doses from compounded vials, where measurement mistakes are common. Our guides on reading an insulin syringe and why DIY microdosing is different cover this.
- If you take it for diabetes or heart protection. The case series participants mostly didn't have diabetes (average A1c before treatment was 5.6%), and none of the studies looked at cardiovascular outcomes. If blood sugar control or heart risk is a main reason you're on the medication, lower exposure could matter in ways that weight alone won't show.
If you and your prescriber want to try it
What the early studies did is a reasonable template to discuss, not a protocol to copy:
- Start from a stable plateau, not in the middle of active loss.
- Change one thing at a time: interval or dose, not both at once.
- Pick a regain threshold in advance (for example, a set number of pounds or a clear return of food noise) that means going back to weekly dosing.
- Keep the supports running: protein, resistance training, sleep, and regular check-ins. Those matter more once the medication is doing less.
- Track more than the scale if you can: waist, how hungry you are late in the gap, and labs if you have metabolic conditions.
A planned trial with your prescriber and a clear "go back to weekly" rule is a very different thing from quietly skipping weeks.
Study findings above are attributed to their authors and were located via PubMed.
This is general education and peer information, not medical advice. Any change to your dosing schedule is a decision to make with your prescriber.